PAKOLA STEVE 4

What Happened Steve Pakola, Chief Medical Officer of REGENXBIO (RGNX), exercised options to acquire 36,725 shares on 2026-07-01 at $7.86 per share (cost $288,659) and immediately sold those 36,725 shares in an open-market transaction at $12.86 each (proceeds $472,284). Earlier, on 2026-06-29 he sold 19,608 shares in the open market at a weighted-average price of $11.04 (proceeds $216,472). Combined, Pakola sold 56,333 shares for total gross proceeds of $688,756. The filing also shows a $0.00 disposition entry for the derivative (the option), reflecting conversion/exercise of the option.

Key Details

• Transaction dates and prices:
  • 2026-06-29: Sold 19,608 shares @ weighted avg $11.04 = $216,472 (executed in multiple trades at $11.00–$11.18).
  • 2026-07-01: Exercised options to acquire 36,725 shares @ $7.86 = $288,659 (Form 4 “M” acquisition).
  • 2026-07-01: Sold 36,725 shares @ $12.86 = $472,284.
  • 2026-07-01: Derivative disposition reported at $0.00 (reflects option extinguished on exercise).
• Total sold: 56,333 shares for $688,756 in gross proceeds; total cash paid to exercise: $288,659.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes:
  • Filing notes at least one sale was effected pursuant to a Rule 10b5‑1 trading plan.
  • The 6/29 sale was executed in multiple trades (prices ranged $11.00–$11.18; reported price is weighted average).
  • The option grant (right to buy 103,698 shares) vested 25% on Jan 2, 2026 and the balance vests monthly over the next 36 months while employed.
• Filing date: Form 4 filed July 1, 2026 — appears timely based on reported transaction dates.

Context

• This was an option exercise followed by an immediate sale (a common “cashless” or same‑day sell-to-cover pattern): Pakola paid the exercise price to convert options into shares and then sold those shares in the market on the same day. The $0.00 derivative disposition entry simply records that the option right was extinguished upon exercise.
• Sales by executives can be routine (liquidity, tax withholding, or plan-driven). Purchases tend to be stronger signals of bullish conviction; this filing is primarily sales. No speculation on motivation is offered — just the reported facts.